title: The synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever/dengue virus leads to strong protection against dengue.
abstract: The dengue envelope glycoprotein (E) is the major component of virion surface and its ectodomain is composed of domains I, II and III. This protein is the main target for the development of a dengue vaccine with induction of neutralizing antibodies. In the present work, we tested two different vaccination strategies, with combined immunizations in a prime/booster regimen or simultaneous inoculation with a DNA vaccine (pE1D2) and a chimeric yellow fever/dengue 2 virus (YF17D-D2). The pE1D2 DNA vaccine encodes the ectodomain of the envelope DENV2 protein fused to t-PA signal peptide, while the YF17D-D2 was constructed by replacing the prM and E genes from the 17D yellow fever vaccine virus by those from DENV2. Balb/c mice were inoculated with these two vaccines by different prime/booster or simultaneous immunization protocols and most of them induced a synergistic effect on the elicited immune response, mainly in neutralizing antibody production. Furthermore, combined immunization remarkably increased protection against a lethal dose of DENV2, when compared to each vaccine administered alone. Results also revealed that immunization with the DNA vaccine, regardless of the combination with the chimeric virus, induced a robust cell immune response, with production of IFN-γ by CD8+ T lymphocytes.
authors.affiliation: Laboratório de Biotecnologia e Fisiologia de Infecções Virais, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
authors.forename: Adriana S
authors.initials: AS
authors.lastname: Azevedo
authors.forename: Antônio J S
authors.initials: AJ
authors.lastname: Gonçalves
authors.forename: Marcia
authors.initials: M
authors.lastname: Archer
authors.forename: Marcos S
authors.initials: MS
authors.lastname: Freire
authors.forename: Ricardo
authors.initials: R
authors.lastname: Galler
authors.forename: Ada M B
authors.initials: AM
authors.lastname: Alves
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D000956:Antigens, Viral / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002460:Cell Line; D003715:Dengue / Q000517:prevention & control*; D053059:Dengue Vaccines / Q000627:therapeutic use*; D003716:Dengue Virus / Q000235:genetics; D007371:Interferon-gamma / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D017434:Protein Structure, Tertiary; D014611:Vaccination / Q000379:methods; D019444:Vaccines, DNA / Q000627:therapeutic use*; D014759:Viral Envelope Proteins / Q000276:immunology*; D015005:Yellow fever virus / Q000235:genetics*
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D000956:Antigens, Viral; D053059:Dengue Vaccines; C051821:E-glycoprotein, Dengue virus type 2; D019444:Vaccines, DNA; D014759:Viral Envelope Proteins; D007371:Interferon-gamma